Brand Intelligence Graph
Company Overview
About Alveus Therapeutics
Alveus Therapeutics is applying mRNA medicine to pulmonary diseases by developing inhaled mRNA formulations that deliver protein replacement or gene editing instructions directly to lung cells. Unlike systemic mRNA therapeutics that require IV infusion and liver targeting, Alveus's inhaled approach delivers mRNA locally to lung epithelial cells, enabling treatment of diseases like idiopathic pulmonary fibrosis (IPF), COPD, and cystic fibrosis with potentially lower doses and fewer systemic side effects.
Business Model & Competitive Advantage
The company's lipid nanoparticle formulations for pulmonary delivery draw on lessons from COVID-19 mRNA vaccine manufacturing and Moderna's pulmonary delivery research. Alveus was founded in 2023 by pulmonology and mRNA delivery experts and raised $150M in a 2025 Series A, reflecting investor enthusiasm for respiratory applications of mRNA technology following vaccine success.
Competitive Landscape 2025–2026
IPF affects 100,000+ patients annually in the U.S. with no curative options — current approved therapies only slow progression. Alveus's IND-enabling studies target a 2026 first-in-human milestone for its lead IPF program, with pipeline expansion into RSV and influenza mRNA vaccines that leverage the inhaled delivery platform.
Key Differentiators
Emerging Innovator
Alveus Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Schrödinger
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has develo
Compare Alveus Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Alveus Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Alveus Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Alveus Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →